阿斯利康(AZN.US)新款COPD吸入器获EMA专家组建议批准

Core Viewpoint - AstraZeneca's Trixeo Aerosphere, an environmentally friendly inhaler for chronic lung diseases, has received a positive recommendation from the European Medicines Agency's expert committee for approval [1][2] Group 1: Product Development - The new version of Trixeo Aerosphere will utilize a next-generation propellant developed by Honeywell, aimed at delivering medication effectively to patients' lungs while reducing carbon footprint [1][2] - The previous version of the inhaler has already been approved in Europe for treating adult patients with Chronic Obstructive Pulmonary Disease (COPD) [1] Group 2: Regulatory Approval - The Committee for Medicinal Products for Human Use (CHMP) recommended the product's approval based on clinical trial results, which showed comparable drug delivery to the current version without new safety risks [1][2] - If the European Commission grants formal approval, Trixeo Aerosphere will become the first inhaler in the EU to use this new delivery mechanism [2] Group 3: Market Impact - The inhaler is projected to generate $978 million in revenue for AstraZeneca in 2024 [2] - Competing products in the COPD market include Sanofi/Regenron's Dupixent, GlaxoSmithKline's Trelegy Ellipta, and Verona Pharma's Ohtuvayre [2]